title: Psychosocial aspects in myasthenic patients treated by plasmapheresis.
abstract: Knowledge about the postintervention psychosocial status of myasthenia gravis (MG) is limited and based on questionnaire studies. In this study, the effects of improvement in muscle strength with plasmapheresis treatment on both quality of life (QoL) and psychological status of MG patients were studied. Between January 2008 and December 2009, 29 MG patients were enrolled to receive one course of plasmapheresis treatment. Differences in baseline and posttherapy clinical, laboratory, and psychosocial measures were determined. The mean MG score decreased from 7.8 points at baseline to 4.2 after plasmapheresis, accompanied by the mean antibody clearance of 56%. Psychosocial tests showed significant pre- and posttherapy differences in illness identity (mean scores 23.62 and 20.79 points, respectively) and disability (mean scores 11.28 and 7.63 points, respectively) (p < 0.01). No significant differences were found for the other indices. Although both anxiety and depression scores did not differ significantly, there was a clear change in patients, as evidenced by their decreases in severity after treatment. The mean mental components scores of QoL were still less than 40 after treatment, indicating that myasthenic patients need assistance in adapting to their disease. Thus, although plasmapheresis treatment achieved immediate improvement of myasthenic symptoms, reduced disability, and better illness identity, both emotional status and QoL did not differ significantly after intervention. Systematical evaluation for patients' illness perceptions and emotional problems are warranted and related strategies should be taken for long-term stabilization of psychosocial function.
authors.affiliation: Department of Nursing, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Yu-Tai
authors.initials: YT
authors.lastname: Chen
authors.forename: Yuanmay
authors.initials: Y
authors.lastname: Chang
authors.forename: Hou-Chang
authors.initials: HC
authors.lastname: Chiu
authors.forename: Jiann-Horng
authors.initials: JH
authors.lastname: Yeh
mesh_terms: D000906:Antibodies / Q000097:blood; D004185:Disability Evaluation; D006801:Humans; D053580:Muscle Strength / Q000502:physiology; D009157:Myasthenia Gravis / Q000097:blood / Q000503:physiopathology / Q000523:psychology* / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods*; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life / Q000523:psychology*; D011950:Receptors, Cholinergic / Q000276:immunology; D012720:Severity of Illness Index; D012917:Social Adjustment; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D011950:Receptors, Cholinergic